Orchid Cellmark Reports Fourth Quarter and Full Year 2007 Financi...( PRINCETON N.J. March 6 /- Orchid ...),Health

PRINCETON, N.J., March 6 /PRNewswire-FirstCall/ -- Orchid Cellmark Inc. (Nasdaq: ORCH), a leading worldwide provider of identity DNA testing services, today reported its financial results for the fourth quarter and full year of 2007.

Total revenues were essentially flat at $15.0 million for the fourth quarter of 2007 compared to $14.9 million for the fourth quarter of 2006. For the full year of 2007, revenues were $60.3 million compared to $56.9 million for the full year of 2006. Revenues for the fourth quarter of 2007 as compared to the fourth quarter of 2006 increased slightly due to increased revenue associated with the acquisition of ReliaGene in October 2007, offset by lower volume of U.K. agricultural testing services and U.S. forensic casework. Revenues for the full year of 2007 increased by $3.4 million as compared to 2006 due to increases in U.S. and U.K. forensic revenues and the impact of the ReliaGene acquisition partially offset by decreases in U.K. agricultural and government and private paternity revenues in the U.S.

Gross margin for the fourth quarter of 2007 was 30% compared to a gross margin of 36% for the fourth quarter of 2006. Gross margin for the fourth quarter of 2007 as compared to the fourth quarter of 2006 was negatively impacted by decreased testing volumes in U.K. agricultural testing services and U.S. forensic casework and costs associated with expanding our U.K. capabilities and capacity in anticipation of new tender awards. Gross margin for the full year of 2007 was 33% compared to a gross margin for the full year of 2006 of 30%. The increase in gross margin for the full year of 2007 compared to 2006 primarily reflects improved pricing in U.S. forensic casework and CODIS testing services and op
'/>"/>